In the phase III multicenter randomized ProPSMA trial, [68 Ga]Ga-PSMA-11 PET/CT resulted in 27% greater accuracy when compared with CT and bone scan for staging of individuals with initial high-risk prostate cancer [26]. This evidence concerns the gene FOLH1 and prostate carcinoma.